Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 10/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 3/20 | 0.46 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 1/20 | 0.34 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300995 | 0.87 | TGFBR1 (0.46) | TGFBR1CYP3A4CYP2C8ACP1TGFBR2 | |
| SCHEMBL2295752 | 0.85 | TGFBR1 (0.45) | TGFBR1CYP3A4CYP2C8ACP1TGFBR2 | |
| SCHEMBL2298659 | 0.85 | TGFBR1 (0.70) | TGFBR1CYP3A4CYP2C8ACP1TGFBR2 | |
| SCHEMBL12425325 | 0.82 | TGFBR1 (0.44) | TGFBR1CYP3A4CYP2C8ACP1TGFBR2 | |
| SCHEMBL12426555 | 0.80 | TGFBR1 (0.49) | TGFBR1CYP3A4CYP2C8TGFBR2MAPK14 | |
| SCHEMBL12426556 | 0.78 | TGFBR1 (0.47) | TGFBR1CYP3A4CYP2C8TGFBR2CCR1 | |
| SCHEMBL2299819 | 0.77 | TGFBR1 (0.47) | TGFBR1CYP3A4ACP1TRPV1MAPK3 | |
| SCHEMBL2299215 | 0.77 | ACP1 (0.43) | TGFBR1CYP3A4CYP2C8ACP1TRPV1 | |
| SCHEMBL12426549 | 0.76 | TGFBR1 (0.53) | TGFBR1CYP3A4CYP2C8TGFBR2CCR1 | |
| SCHEMBL12424699 | 0.76 | ACP1 (0.50) | ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539336-B1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| CN-103097381-A | 1, 8-naphthyridines as kinase inhibitors | MERCK PATENT GMBH | 2013-05-08 | — | — | CN | disclosed |
| EP-2539336-A2 | HETARYLAMINONAPHTHYRIDINES | Merck Patent GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | ATP5ME, ATP5F1A, ATP5F1D | TGFBR1 3742/4885CYP3A4 828/4885CYP2C8 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.